Unlocking the Next Frontier in Immuno-Oncology: Powering T and NK Cell Therapies with Nanotein’s Innovative Platforms

Powering T and NK Cell Therapies with Nanotein’s Innovative Platforms

In the ever-evolving field of immuno-oncology, the race to develop the most effective cell-based therapies has never been more urgent—or more promising.

T cells and NK cells are at the heart of this revolution, and harnessing their full therapeutic potential is key to pushing the boundaries of cancer treatment.

With this in mind, Tebubio is excited to announce a new partnership with Nanotein, an innovator in immune cell activation and expansion technologies. As Nanotein’s distributor in Europe, we are proud to introduce STEM-T, EVEN-T, and GROW-NK—three innovative solutions designed to accelerate advancements in T cell and NK cell therapies.

But how can we push those boundaries even further?

This is where Nanotein’s STEM-T, EVEN-T, and GROW-NK platforms come into play. These products, each designed with precision and built on the powerful NanoSpark core technology, provide researchers with the tools needed to take immunotherapy studies to the next level. Whether you’re working on optimising CD8+ T cell expansion, fine-tuning the CD4:CD8 ratio, or boosting NK cell cytotoxicity, these solutions offer efficacy, flexibility, and reliability across a variety of experimental conditions.

Here’s why these products stand out:

NanoSpark® STEM-T Soluble T Cell Activator: Maximise your CD8+ cell yields, empowering your research in tumor destruction and immune response enhancement.

NanoSpark® EVEN-T Soluble T Cell Activator: Achieve precise modulation of the CD4:CD8 ratio, a crucial factor in understanding immune balance and developing therapies that fight cancer while reducing the risk of autoimmune reactions.

NanoSpark® GROW-NK Soluble Activator: Boost NK cell expansion and cytotoxicity without the hassle of feeder cells. Feeder-free technology not only simplifies your workflow but also ensures greater consistency and reliability in your research results.

A Shift Toward Feeder-Free Precision

Traditional NK cell expansion often relies on feeder cells, introducing variability and added complexity to research protocols. GROW-NK eliminates this obstacle with its feeder-free system, optimised to deliver superior activation and expansion while enhancing cytotoxicity beyond other commercial products. With anti-NKp46 and anti-CD2 antibodies bound to the NanoSpark core, GROW-NK offers unparalleled flexibility in serum and serum-free conditions, making it the go-to solution for advancing NK cell-based immunotherapies.

How These Innovations Transform Your Immuno-Oncology Research?

The ability to rapidly expand and manipulate immune cells directly correlates with the speed and success of therapeutic development. With STEM-T, EVEN-T, and GROW-NK, you’ll have the tools necessary to:

• Boost T cell responses in ways that make cancer therapies more effective.
• Tailor immune cell ratios for precision-targeted therapies.
• Expand NK cells with higher cytotoxic power, enhancing your approach to cancer cell eradication.

These products are protein-based, soluble, and optimised for use in a wide variety of culture environments, ensuring compatibility with your research protocols, whether you’re using serum-based or serum-free media.

• References

  1. Mamaghani S, Penna RR, Frei J, Wyss C, Mellett M, Look T, Weiss T, Guenova E, Kündig TM, Lauchli S, et al. Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo. Cells. 2024; 13(15):1242. https://doi.org/10.3390/cells13151242

Explore In Vitro Modeling Services

Accelerate drug screening with personalized in vitro models with our Contract Reserach Services experts that can support your cell-based assays, 3D models, organ-on-chip, disease modeling, biobanking and custom 2D/3D modeling development projects. Learn how we can partner to advance your research.